HVB MINI FUTURE BEAR - ASTRAZENECA | Real-time BOERSE MUENCHEN 07:47:01 2024-05-27 EDT | ||
| 0.55 EUR | +10.00% |
|
| Current month | -39.76% | ||
| 1 month | -68.55% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24-05-27 | 0.55 | +10.00% |
| 24-05-24 | 0.5 | +8.70% |
| 24-05-23 | 0.46 | -8.00% |
| 24-05-22 | 0.5 | +21.95% |
| 24-05-21 | 0.41 | -48.10% |
Real-time BOERSE MUENCHEN
Last update May 27, 2024 at 07:47 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HB7ZXL |
| ISIN | DE000HB7ZXL0 |
| Date issued | 2022-06-28 |
| Strike | 12,715 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.8 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.02 € |
|---|---|
| Lowest since issue | 0.36 € |
| Spread | 0.03 € |
| Spread % | 5.17% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7
USD
Average target price
170.1
USD
Spread / Average Target
+8.53%
- Stock Market
- Certificates
- Certificat
